Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C

by Dr. Trupti Shirole on  December 4, 2011 at 5:03 PM Clinical Trials News
RSS Email Print This Page Comment
Bristol-Myers Squibb Co. will collaborate with a unit of Johnson & Johnson to study a potential combination therapy for chronic hepatitis C.
 Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C
Bristol-Myers and Johnson & Johnson to Study Combination Therapy for Hepatitis C
Advertisement

The companies will test the potentially positive effects of combining Johnson & Johnson's drug TMC435 with Bristol-Myers Squibb's daclatasvir. The clinical trials will begin in the first half of 2012 and will include a combination of the two drugs, the drugs plus pegylated interferon and ribavirin, and the drugs plus ribavirin.

Advertisement
The terms of their partnership were not disclosed.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Hepatitis A Hepatitis B Vasculitis Reiki and Pranic Healing Silent Killer Diseases Liver Aplastic Anemia Hepatitis C Combination Therapy for High Blood Pressure Hepatitis 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive